NBHL

Since 2008, NBHL has focused on establishing a technology platform for the generation of functional mAbs targeting GPCRs to pioneer a new field in GPCR-targeted drug discovery, in collaboration with universities and other partners in Japan. The result is a proprietary technology platform, which is now attracting interest for its potential to be used as a research tool and for the generation of therapeutic antibodies. NBHL has used the technology platform to discover promising mAbs targeting GPCRs for the treatment of respiratory diseases and chronic inflammation, which are being progressed towards clinical development. In addition, NBHL has expanded its R&D program to focus on central nervous system (CNS) disorders, in particular insomnia and night wandering associated with Alzheimer's disease. NBHL has discovered novel compounds for insomnia associated with Alzheimer's disease and is progressing these towards clinical development. The technology platform for mAbs targeting GPCRs can also help to accelerate internal R&D programs for CNS. NBHL's core business model is to provide the pharmaceutical industry with innovative drug candidates, including mAbs targeting GPCRs and small molecules. Through collaborations with pharmaceutical companies, NBHL operates its proprietary technology platform to run drug discovery programs according to specifications provided by its customers.